Standout Papers
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (2009)
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (2021)
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) (2011)
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008)
Immediate Impact
11 from Science/Nature 183 standout
Citing Papers
Prostate Cancer
2025 Standout
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Works of Alison Armour being referenced
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Alison Armour | 9370 | 7273 | 1308 | 2514 | 37 | 11.2k | |
| A Płużańska | 8129 | 6183 | 1355 | 3165 | 65 | 11.4k | |
| Steven D. Averbuch | 7370 | 7926 | 723 | 2824 | 57 | 10.9k | |
| Robert T. Heelan | 7065 | 5459 | 997 | 2490 | 78 | 9.6k | |
| Ross A. Okimoto | 8004 | 7168 | 731 | 4847 | 33 | 11.9k | |
| Christian Manegold | 12736 | 9216 | 1104 | 3108 | 109 | 15.8k | |
| Patricia L. Harris | 7435 | 6573 | 691 | 3943 | 14 | 10.4k | |
| Sarada Gurubhagavatula | 6774 | 6093 | 605 | 4143 | 17 | 10.3k | |
| Brian W. Brannigan | 8986 | 9398 | 825 | 5950 | 25 | 15.1k | |
| Sara M. Haserlat | 6903 | 6076 | 629 | 3627 | 10 | 9.7k | |
| Raffaella Sordella | 8457 | 7898 | 828 | 6830 | 33 | 14.5k |
All Works
Loading papers...